

3. (Amended) The derivative of an antibody according to claim 1, wherein the monoclonal antibody comprises CDR1, CDR2 and CDR3 of H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

4. (Amended) The derivative of an antibody according to claim 1, wherein the monoclonal antibody comprises CDR1, CDR2 and CDR3 of L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

5. (Amended) The derivative of an antibody according to claim 1, wherein the monoclonal antibody comprises:

CDR1, CDR2 and CDR3 of a heavy chain (H chain) variable region (V region) having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and

CDR1, CDR2 and CDR3 of a light chain (L chain) V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

10. (Amended) The derivative of a human chimeric antibody according to claim 8, wherein the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55.

11. (Amended) The derivative of a human chimeric antibody according to claim 8, wherein the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

12. (Amended) The derivative of a human chimeric antibody according to claim 8, wherein

the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55; and

the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

13. (Amended) The derivative of a human chimeric antibody KM871 according to claim 8, wherein

the H chain V region comprises the amino acid sequence represented by SEQ ID NO:55; and

the L chain V region comprises the amino acid sequence represented by SEQ ID NO:56.

17. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the antibody comprises CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

18. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the antibody comprises CDR1, CDR2 and CDR3 of the L chain V

HANAI et al  
Serial No. **Unknown**

region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

19. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the antibody comprises:

CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and

CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

20. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9.

21. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

22. (Amended) The derivative of a human CDR-grafted antibody according to claim 14, wherein the H chain V region and the L chain V region of the antibody comprises the amino acid sequences represented by SEQ ID NO:9 and SEQ ID NO:54, respectively.

23. (Amended) The derivative of a human CDR-grafted antibody KM8871 according to claim 14, wherein

the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

25. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises amino acid sequences of an H chain V region and an L chain V region of a monoclonal antibody against ganglioside GD3 produced by a hybridoma.

26. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:55.

27. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:56.

28. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises:

an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:55; and

an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:56.

29. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises amino acid sequences of an H chain V region and an L chain V region of a human CDR-grafted antibody against ganglioside GD3.

30. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:9.

31. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:54.

32. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises:

an H chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:9; and

an L chain V region of the antibody having the amino acid sequence represented by SEQ ID NO:54.

33. (Amended) The derivative of an antibody fragment according to claim 1, wherein the antibody fragment comprises CDR1, CDR2 and CDR3 of an H chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

34. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises CDR1, CDR2 and CDR3 of an L chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

35. (Amended) The derivative of the antibody fragment according to claim 1, wherein the antibody fragment comprises:

CDR1, CDR2 and CDR3 of an H chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5; and

CDR1, CDR2 and CDR3 of an L chain V region of the antibody having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8.

36. (Amended) The derivative of a monoclonal antibody or the antibody fragment thereof according to claim 1, wherein the protein is a cytokine.

42. (Amended) A DNA which encodes the derivative of a monoclonal antibody or the derivative of the antibody fragment thereof which specifically reacts with ganglioside GD3 according to claim 1.

47. (Amended) A process for producing an antibody, which comprises:  
culturing the transformant according to claim 44 in a culture medium to produce and accumulate the derivative of a monoclonal antibody or the derivative of the antibody fragment thereof in the culture; and  
recovering the derivative of the antibody or the derivative of the antibody fragment thereof from the culture.

52. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein the antibody comprises CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively.

53. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein the antibody comprises CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8, respectively.

54. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein the antibody comprises:

CDR1, CDR2 and CDR3 of the H chain V region having the amino acid sequences represented by SEQ ID NOs:3, 4 and 5, respectively; and

CDR1, CDR2 and CDR3 of the L chain V region having the amino acid sequences represented by SEQ ID NOs:6, 7 and 8.

55. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9.

56. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

57. (Amended) The human CDR-grafted antibody or the antibody fragment thereof according to claim 49, wherein

the H chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region of the antibody comprises the amino acid sequence represented by SEQ ID NO:54.

58. (Amended) The human CDR-grafted antibody KM8871 or the antibody fragment thereof according to claim 49, wherein



the H chain V region of the antibody comprises the amino acid sequence  
represented by SEQ ID NO:9; and

the L chain V region of the antibody comprises the amino acid sequence  
represented by SEQ ID NO:54.

59. (Amended) A DNA which encodes the human CDR-grafted antibody or the  
antibody fragment thereof which specifically reacts with ganglioside GD3 according to  
claim 48.

63. (Amended) A process for producing an antibody, which comprises:  
culturing the transformant according to claim 61 in a culture medium to produce  
and accumulate the human CDR-grafted antibody or the antibody fragment thereof in  
the culture; and

recovering the antibody or the antibody fragment thereof from the culture.

64. (Amended) A medicament comprising at least one selected from the  
derivative of a monoclonal antibody and the derivative of the antibody fragment thereof  
according to claim 1 and the human CDR-grafted antibody and the antibody fragment  
thereof which specifically reacts with ganglioside GD3.

65. (Amended) A therapeutic agent for cancers, comprising, as an active  
ingredient, at least one selected from the derivative of a monoclonal antibody and the  
derivative of the antibody fragment thereof according to claim 1 and the human CDR-

HANAI et al  
Serial No. **Unknown**

grafted antibody and the antibody fragment thereof which specifically reacts with ganglioside GD3.

66. (Amended) A diagnostic agent for cancers, comprising, as an active ingredient, at least one selected from the derivative of a monoclonal antibody and the derivative of the antibody fragment thereof according to claim 1 and the human CDR-grafted antibody and the antibody fragment thereof which specifically reacts with ganglioside GD3.

---